368441-98-9

Usage

Uses

Used in Research Applications:
2-Piperazineacetic acid, methyl ester (9CI) is used as a biochemical for proteomics research, where it plays a crucial role in organic synthesis processes. Its reactivity and properties make it a valuable compound for scientific studies and experiments.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Piperazineacetic acid, methyl ester (9CI) is employed as a key intermediate or building block for the synthesis of various complex molecules. Its ester group allows for further reactions and modifications, making it a versatile component in the creation of new compounds.
Used in Pharmaceutical Development:
Although specific data about its applications and effects are limited, 2-Piperazineacetic acid, methyl ester (9CI) has the potential to be used in pharmaceutical development. Its unique structure and reactivity may contribute to the discovery of new drugs or therapeutic agents, particularly in the areas of proteomics and related fields. Further research and development are needed to fully explore its potential in this industry.

Upstream product

• 183742-32-7 1,4-dibenzyl-2-methoxycarbonylmethylpiperazine 
• 70403-11-1 2-(1,4-dibenzyl-2-piperazinyl)acetonitrile 
• 94437-04-4 1,4-dibenzyl-2-hydroxypiperazine 
• 72351-59-8 ethyl 1,4-dibenzylpiperazin-2-carboxylate 
• 24225-89-6 2-chloromethyl-1,4-bis(phenylmethyl)piperazine 
• 1117-71-1 methyl 4-bromocrotonate 

Downstream Products

• 183742-33-8 3-(methoxycarbonylmethyl)piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

NOVEL IN-VIVO PROBE FOR REAL TIME LONGITUDINAL MONITORING OF INDUCIBLE NITRIC-OXIDE SYNTHASE IN LIVING CELLS AND ANIMALS

The present disclosure relates to an in vivo fluorescent or radioactive probe represented by a compound of formula I which is capable of longitudinal imaging of inducible nitric oxide synthase (iNOS) expression in living cells and living animals on a real time basis. The probe of the present disclosure can exhibit specific and high affinity binding to the iNOS enzyme with reduced enzyme inhibitory property and also enables longitudinal monitoring of iNOS expression along with its activity or NO production in a same experimental subject throughout the progression of a physiological or disease process without employing separate subjects as controls and experimental. The present disclosure further provides a rapid and inexpensive real time method for visualizing iNOS expression and its activity in living cells and living animals precisely, conveniently and reversibly along with simultaneous in vivo imaging of its catalytic product, nitric oxide (NO) in live physiological settings.

DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS

The present invention relates to 11-(piperazin-l-yl)dibenzo[b,f][l,4]oxazapine compounds of the formula I (I) where the variables are as defined herein, their salts and pharmaceutically acceptable compositions thereof. Methods of preparing these compounds are also described. These compounds may be used in the treatment of disorders such as schizophrenia, treatment resistant schizophrenia, bipolar disorder, psychotic depression, treatment resistant depression, schizophrenia-associated depression, treatment resistant OCD, autism, senile psychosis, psychotic dementia, L-DOPA induced psychosis, psychogenic polydipsia, psychotic symptoms of neurological disorders, sleep disorders.

Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors

By the screening of a combinatorial library for inhibitors of nitric oxide (NO) formation by the inducible isoform of nitric oxide synthase (iNOS) using a whole-cell assay, 2-(imidazol-1-yl)pyrimidines were identified. Compounds were found to inhibit the dimerization of iNOS monomers, thus preventing the formation of the dimeric, active form of the enzyme. Optimization led to the selection of the potent, selective, and orally available iNOS dimerization inhibitor, 21b, which significantly ameliorated adjuvant-induced arthritis in a rat model. Analysis of the crystal structure of the 21b-iNOS monomer complex provided a rationalization for both the SAR and the mechanism by which 21b blocks the formation of the protein-protein interaction present in the dimeric form of iNOS.